as 04-01-2025 3:39pm EST
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
Founded: | 2020 | Country: | United States |
Employees: | N/A | City: | MIAMI |
Market Cap: | 20.5M | IPO Year: | 2023 |
Target Price: | $14.00 | AVG Volume (30 days): | 359.3K |
Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.51 | EPS Growth: | N/A |
52 Week Low/High: | $0.51 - $5.01 | Next Earning Date: | 05-12-2025 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
MIRA Breaking Stock News: Dive into MIRA Ticker-Specific Updates for Smart Investing
ACCESS Newswire
8 hours ago
TipRanks
7 days ago
MT Newswires
8 days ago
ACCESS Newswire
8 days ago
Benzinga
8 days ago
Zacks Small Cap Research
8 days ago
TipRanks
18 days ago
MT Newswires
19 days ago
The information presented on this page, "MIRA MIRA Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.